Journal Article10.1158/2159-8290.cd-24-0015
Advancing Cancer Interception.
9
TL;DR: Targeted therapies and "immuno-interception" may eliminate premalignant lesions and require clinical trial and treatment paradigms altogether distinct from current approaches.
read more
Abstract: Rapid advances in technology and therapeutics, along with better methods to discern who is at risk for cancer by genetic testing and other means, has enabled the development of cancer interception. Targeted therapies and "immuno-interception" may eliminate premalignant lesions and require clinical trial and treatment paradigms altogether distinct from current approaches.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Technology and Future of Multi-Cancer Early Detection
Danny A. Milner,Jochen K. Lennerz +1 more
TL;DR: The potential of multi-omics approaches, which integrate genomic, transcriptomic, proteomic, and metabolomic data, to enhance early cancer detection are explored.
6
Nonlinear progression across the occult transition establishes cancer lethality
Joshua D. Ginzel,Henry Chapman,Joelle E. Sills,Edwin J. Allen,Lawrence S. Barak,Robert D. Cardiff,Alexander Borowsky,H. K. Lyerly,Bruce W. Rogers,Joshua C. Snyder +9 more
TL;DR: The quantitatively traced the invisible and visible phases of tumorigenesis in the mammary gland for more than two-thousand tumors to illustrate how nonlinear growth across an occult checkpoint can account for a paradoxical increase in early-stage cancer detection without a dramatic reduction in metastatic burden.
1
Precision preclinical modeling to advance cancer treatment
David H. Gutmann,Jesse S. Boehm,Elinor K. Karlsson,Eric Padron,Mukund Seshadri,Deann Wallis,Joshua C. Snyder +6 more
TL;DR: Researchers at the National Cancer Institute's Oncology Models Forum discuss the benefits and limitations of precision preclinical models in cancer treatment, highlighting their potential to inform future prevention and treatment approaches across the disease continuum.
1
La vision des cliniciens sur le dépistage du cancer du sein
Lucie Véron,Anna Ilenko,Agustina Ipina,Suzette Delaloge +3 more
Engineering and biofabrication of early cancer models
Haylie R. Helms,Alexander E. Davies,Carolyn E. Schutt,Ellen M. Langer,Rebekka Duhen,Prima Dewi Sinawang,Demir Akin,Utkan Demirci,Sadik C. Esener,Rebecca C. Fitzgerald,Luiz E. Bertassoni,Haylie R. Helms,Alexander E. Davies,Carolyn E. Schutt,Ellen M. Langer,Rebekka Duhen,Prima Dewi Sinawang,Demir Akin,Utkan Demirci,Sadik C. Esener,Rebecca C. Fitzgerald,Luiz E. Bertassoni +21 more
References
Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths
Ann G. Zauber,Sidney J. Winawer,Michael J. O'Brien,Iris Lansdorp-Vogelaar,Marjolein van Ballegooijen,Benjamin F. Hankey,Weiji Shi,John H. Bond,Melvin Schapiro,Joel F. Panish,Stewart Et,Jerome D. Waye +11 more
TL;DR: Findings support the hypothesis that colonoscopic removal of adenomatous polyps prevents death from colorectal cancer.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt,Judy Garber,Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmaña,Susan M. Domchek,Karen A. Gelmon,Simon J. Hollingsworth,Larissa A. Korde,Barbro Linderholm,Hanna Bandos,Hanna Bandos,Elżbieta Senkus,Jennifer Marie Suga,Zhimin Shao,Andrew W. Pippas,Zbigniew Nowecki,Tomasz Huzarski,Patricia A. Ganz,Peter Lucas,Peter Lucas,Nigel Baker,Sibylle Loibl,Robin McConnell,Martine Piccart,Rita K. Schmutzler,Guenther G. Steger,Joseph P. Costantino,Amal Arahmani,Norman Wolmark,Norman Wolmark,Eleanor McFadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Greg Yothers,Christine Campbell,Charles E. Geyer +43 more
TL;DR: In this paper, a poly(adenosine diphosphate-ribose) polymerase inhibitor was proposed to target cancers with defects in homologous recombination repair by synthetic lethality.
1.1K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
1.1K
High grade serous ovarian carcinomas originate in the fallopian tube
S. Intidhar Labidi-Galy,S. Intidhar Labidi-Galy,Eniko Papp,Dorothy Hallberg,Noushin Niknafs,Noushin Niknafs,Vilmos Adleff,Michaël Noë,Rohit Bhattacharya,Rohit Bhattacharya,Marian Novak,Siân Jones,Jillian Phallen,Carolyn Hruban,Michelle S. Hirsch,Douglas I. Lin,Douglas I. Lin,Lauren E. Schwartz,Cecile L. Maire,Jean-Christophe Tille,Michaela Bowden,Ayse Ayhan,Laura D. Wood,Robert B. Scharpf,Robert J. Kurman,Tian Li Wang,Ie Ming Shih,Rachel Karchin,Rachel Karchin,Ronny Drapkin,Ronny Drapkin,Ronny Drapkin,Victor E. Velculescu +32 more
TL;DR: Genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients are analyzed and evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian cancer, with metastases following rapidly thereafter.
Selenium for preventing cancer
Gabriele Dennert,Marcel Zwahlen,Maree Brinkman,Marco Vinceti,Maurice P. Zeegers,Markus Horneber +5 more
TL;DR: Findings have limitations due to study design, quality and heterogeneity that complicate interpretation of the summary statistics, and some studies suggested that genetic factors may modify the relation between selenium and cancer risk-a hypothesis that deserves further investigation.
584